Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE versus HEXADROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE versus HEXADROL.
Betamethasone vs HEXADROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression, resulting in anti-inflammatory and immunosuppressive effects. It also suppresses the hypothalamic-pituitary-adrenal axis.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
0.6 to 9 mg/day orally in divided doses; intramuscularly, 0.5 to 9 mg/day; intravenously, up to 12 mg/day; topical (as valerate or dipropionate) applied thinly to affected area once to twice daily.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
None Documented
None Documented
Clinical Note
moderateBetamethasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin."
Clinical Note
moderateBetamethasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin."
Clinical Note
moderateBetamethasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 6.4 hours (range 4.3-9.4 hours). Clinically, adrenal suppression lasts 2.7-3.5 days after single dose.
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Primarily renal: ~60% as metabolites, <5% unchanged. Biliary/fecal: ~15-20%.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Category A/B
Category C
Corticosteroid
Corticosteroid
Betamethasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin."